Wait For Valeant's (VRX) 10K - RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
Valeant Pharma (VRX) Short Interest Surges 56% - Guggenheim
April 11, 2016 5:42 PM EDTIn analyzing the latest short interest data for the Specialty Pharmaceutical sector, Guggenheim's Louise Chen notes that Valeant Pharma (NYSE: VRX) short interest rose 56.1% - the largest increase in the sector.
Valeant Pharma short interest was at 18,021,306 shares as of 03/31/2016, versus 11,548,303... More
Valeant (VRX) Enters Amended Credit Agreement; Extends Date of 10-K Filing, Waives Cross-Default
April 11, 2016 4:28 PM EDTValeant Pharma (NYSE: VRX) disclosed the following on Monday:
Item 1.01. Entry Into a Material Definitive Agreement.
On April 11, 2016, Valeant Pharmaceuticals International, Inc. (the Company) entered into an amendment and waiver (Amendment No. 12) to its Third Amended and Restated Credit and Guaranty Agreement, dated as of February 13, 2012 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the Credit Agreement).
Amendment No. 12 extends the deadline for filing (i) the Companys Form 10-K for the fiscal year ended December 31, 2015 to May 31, 2016 and (ii) the Companys Form 10-Q for the... More
